Please login to the form below
Lupin
This page shows the latest Lupin news and features for those working in and with pharma, biotech and healthcare.
Boehringer links up with Trutino for cancer R&D
In September 2019, the German drugmaker also made a $720m play for a MEK inhibitor from India’s Lupin that it is looking to pair with its stable of KRAS inhibitors. ... The Lupin deal came only a few short weeks after Boehringer partnered with The
Latest news
-
Boehringer bolsters KRAS push with $720m Lupin deal
Signs of progress in the field are emerging. Boehringer Ingelheim has licensed a MEK inhibitor from India’s Lupin that it intends to pair with its stable of KRAS inhibitors, a ... For Lupin, Boehringer is the second big biopharma partner for its
-
Biogen files Tecfidera follow-up in the US
Earlier this month Indian drugmakers Lupin Labs and Shilpa Medicare both won tentative FDA approval for generic dimethyl fumarate capsules, although they have not indicated when they intend to place the
-
India denies Vertex patent on cystic fibrosis drug Orkambi
The patent was opposed by the Indian Pharmaceutical Alliance (IPA), a trade organisation representing India's larger pharmaceutical companies, including Cipla, Dr Reddy's Labs, Lupin, Nicholas Piramal, Ranbaxy and Wockhardt.
-
Pfizer inks $360m deal to buy InnoPharma
Other notable M&A activity in the sector includes Par Pharma's $490m deal to buy JHP Pharmaceuticals in January, Lupin Laboratories' agreement to buy Nanomi of the Netherlands the following
-
EU hits Servier and generic firms with €428m 'pay-for-delay' fine
The generics companies implicated in the scandal - Niche/Unichem, Matrix (part of Mylan), Teva, Krka and Lupin - are facing penalties of 97m between them. .
Boehringer bolsters KRAS push with $720m Lupin deal
Biogen files Tecfidera follow-up in the US
India denies Vertex patent on cystic fibrosis drug Orkambi
Pfizer inks $360m deal to buy InnoPharma
EU hits Servier and generic firms with €428m 'pay-for-delay' fine
More from news
Approximately 2 fully matching, plus 24 partially matching documents found.
Latest Intelligence
-
Deal Watch August 2016
165. Shionogi (JP). Kyowa (JP) (Lupin). Asset acquisition Japan. 21 branded products in Japan with $90m sales.
-
Pharma deals in July 2015
The consolidation in the generics industry has also increased with Lupin's acquisition of the US generics company Gavis for $880m at a high sales multiple of nine but which has ... In July Lupin also acquired a factory in Russia and a speciality product
Deal Watch August 2016
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest appointments
-
Minoyrx Therapeutics appoints chief medical officer
Dr Uwe Meya joins from Lupin Atlantis Holdings. Spanish orphan disease specialist Minoryx Therapeutics has appointed Dr Uwe Meya as its new chief medical officer. ... He joins the Barcelona-based drug development company from Lupin Atlantis Holdings,
-
Lupin appoints Thierry Volle president for EMEA
He moves to the company from Vifor. Mumbai-based pharma company Lupin has appointed Thierry Volle to lead its Europe, Middle-East and Africa operations as president. ... Vinita Gupta, Lupin's chief executive officer, said: "We are delighted to have
-
Dr Maurice Chagnaud appointed as new CEO of Polpharma
He will join the company next week from Lupin where he was a group president with an inhalation remit for Europe, Russia &CIS. ... We are impressed by the extensive experience of Mr Chagnaud, gained in international companies such as Merck Generics, Teva
-
Lupin names chief corporate development officer
Theresa Stevens has experience at Novartis and Aptalis. Lupin has appointed Theresa Stevens as chief corporate development officer for its global operations. ... Lupin's decision to hire Stevens follows its appointment earlier this year of Teva's Dr
-
Lupin appoints European president
countries. He will also be responsible for developing Lupin's core strategy for inhalation across all developed markets. ... Prior to joining Lupin, Dr Chagnaud was senior VP, Central and Eastern Europe, at Israel-based Teva.
Minoyrx Therapeutics appoints chief medical officer
Lupin appoints Thierry Volle president for EMEA
Dr Maurice Chagnaud appointed as new CEO of Polpharma
Lupin names chief corporate development officer
More from appointments
Approximately 3 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Account Management
-
Competitive Salary Offered
- Account Manager / Senior Account Manager - Creative MedComms - C...
-
Excellent Remuneration
-
Senior Account Executive
-
Competitive Salary
- Head of Strategic Planning, Healthcare Advertising/ Brand comms,...
-
Six figure salary
-
Publications Director
-
Competitive Salary
-
Associate Account Director
-
Competitive Salary
- Group Account Director, Healthcare Advertising/ Brand comms, Lon...
-
8 month contract up to £90K
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Senior & Principal Medical Writer
-
Competitive Salary Offered
- Senior Account / Programme Manager - MedComms - Buckinghamshire
-
Highly Competitive Remuneration packages
-
Account Manager
-
Competitive Salary
- Account Manager - Creative Healthcare Communications - South Wes...
-
Excellent Remuneration
-
Senior Medical Writer
-
Competitive Salary
- Senior Account Manager/ Account Director
-
Competitive Salary Offered
- Senior Medical Writer– Medical Education – Oxford - London
-
Excellent Remuneration Package
-
Medical Editor
-
Competitive Salary
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- Merck & Co reveals plans for women’s health spinoff Organon
- Positive results for GSK/CureVac’s COVID-19 vaccine
- EMA launches rolling review of GSK/Vir Biotech’s mAb for early COVID-19
- Biogen and Capsigen to collaborate on gene therapies
- CanSinoBIO considers booster jab for COVID-19 vaccine
- Research Partnership’s MedTech Division appoints two Directors
- VMLY&Rx launches new payer agency in the US
- Biogen and Envisagenics to advance RNA splicing research for CNS diseases
- Positive results for GSK/CureVac’s COVID-19 vaccine
- New trial data for Keytruda in triple-negative breast cancer
- NICE recommends Keytruda for colorectal cancer patients with rare mutations
- Merck & Co reveals plans for women’s health spinoff Organon
- UK launches subscription-style payment pilot to incentivise pharma antibiotics R&D
- Why female mentorship is so powerful in pharma
- Positive results for GSK/CureVac’s COVID-19 vaccine
- Avoiding A Series of Unfortunate Events: launch lessons from lockdown
- Can protein degraders unlock ‘undruggable’ drug targets?
PMHub
Fishawack Health
Fishawack Health is the leading global commercialization partner for the modern life science era. Established in 2001 and headquartered in...
Latest intelligence
- How innovating study sites can improve patient recruitment efficiency
- There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
- Avoiding A Series of Unfortunate Events: launch lessons from lockdown
- Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
- 6 reasons patients drop out of clinical trials and 6 ways to fix it
- If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....
